Citizens maintains outperform rating on LeMaitre Vascular stock

ArchivedSingle Source|2 articles|1 sources|1 blocks

Detected: Updated: Analyzed:

Finance Healthcare Earnings

Reported Facts

Observable data points shared across all narratives

•Citizens maintained an outperform rating on LeMaitre Vascular stock on February 20, 2026
•Citizens reiterated its stock rating on Cushman & Wakefield on the same date

What Could Happen If...

▸If LeMaitre Vascular reports strong quarterly earnings Citizens and other investors may increase buying interest in LeMaitre Vascular stock

Market Exposure

StocksLeMaitre VascularUpward Pressure

If Citizens maintains an outperform rating, it may encourage investor demand, applying upward pressure on LeMaitre Vascular's stock price

This is not investment advice. Market exposure is based on conditional event analysis.

Key Actors

Instruments

📈Cushman & Wakefield stock 📈LeMaitre Vascular stock

Organizations

🏛Citizens 🏛Cushman & Wakefield 🏛LeMaitre Vascular

Source Coverage

FINANCE

2 articles

More coverage on this story

Signals

Single-block coverage

Primary Sources (2)

FINANCEInvesting.com - NewsLeMaitre Vascular stock rating maintained at outperform by Citizens FINANCEInvesting.com - NewsCitizens reiterates Cushman & Wakefield stock rating on solid 2025

On February 20, 2026, Citizens reaffirmed its outperform rating on LeMaitre Vascular's stock, signaling continued confidence in the company's performance and prospects. This rating suggests that Citizens expects LeMaitre Vascular to perform better than the broader market. The reaffirmation comes alongside Citizens' reiteration of its rating on Cushman & Wakefield, indicating a consistent investment approach across different sectors. LeMaitre Vascular, a medical device company specializing in vascular surgery products, remains a focus for investors monitoring healthcare equities.